- Home
- CMPR vs MLYS Comparison
CMPR vs MLYS Comparison
Compare CMPR & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMPR
- MLYS
- Stock Information
- Founded
- CMPR 1994
- MLYS 2019
- Country
- CMPR Ireland
- MLYS United States
- Employees
- CMPR N/A
- MLYS N/A
- Industry
- CMPR Publishing
- MLYS Biotechnology: Pharmaceutical Preparations
- Sector
- CMPR Consumer Discretionary
- MLYS Health Care
- Exchange
- CMPR Nasdaq
- MLYS Nasdaq
- Market Cap
- CMPR 1.1B
- MLYS 1.0B
- IPO Year
- CMPR N/A
- MLYS 2023
- Fundamental
- Price
- CMPR $42.91
- MLYS $13.48
- Analyst Decision
- CMPR Strong Buy
- MLYS Strong Buy
- Analyst Count
- CMPR 2
- MLYS 4
- Target Price
- CMPR $62.50
- MLYS $27.00
- AVG Volume (30 Days)
- CMPR 213.9K
- MLYS 667.1K
- Earning Date
- CMPR 07-30-2025
- MLYS 08-12-2025
- Dividend Yield
- CMPR N/A
- MLYS N/A
- EPS Growth
- CMPR 83.61
- MLYS N/A
- EPS
- CMPR 5.97
- MLYS N/A
- Revenue
- CMPR $3,366,207,000.00
- MLYS N/A
- Revenue This Year
- CMPR $4.65
- MLYS N/A
- Revenue Next Year
- CMPR $3.16
- MLYS N/A
- P/E Ratio
- CMPR $7.14
- MLYS N/A
- Revenue Growth
- CMPR 3.64
- MLYS N/A
- 52 Week Low
- CMPR $35.21
- MLYS $8.24
- 52 Week High
- CMPR $104.92
- MLYS $18.38
- Technical
- Relative Strength Index (RSI)
- CMPR 45.36
- MLYS 35.32
- Support Level
- CMPR $42.81
- MLYS $12.98
- Resistance Level
- CMPR $47.79
- MLYS $16.67
- Average True Range (ATR)
- CMPR 1.69
- MLYS 0.81
- MACD
- CMPR -0.29
- MLYS -0.33
- Stochastic Oscillator
- CMPR 15.04
- MLYS 13.56
About CMPR Cimpress plc (Ireland)
Cimpress PLC invests in and builds customer-focused, entrepreneurial, mass-customization businesses for the long term. Mass customization seeks to produce goods and services to meet individual customer needs with near mass production efficiency. Its products and services include a broad range of marketing materials, business cards, signage, promotional products, logo apparel, packaging, books and magazines, wall decor, photo merchandise, invitations and announcements, design and digital marketing services, and other categories. The company's segment includes Vista; PrintBrothers; The Print Group; National Pen and All Other Businesses. It generates maximum revenue from the Vista segment.
About MLYS Mineralys Therapeutics Inc.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.